Europe Biodefense Market

Europe Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026

Report Id: KBV-5232 Publication Date: February-2021 Number of Pages: 68
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Biodefense Market, by Product
1.4.2 Europe Biodefense Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Recent Industry Wide Strategic Developments
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Approvals
3.1.3 Acquisition and Mergers
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players

Chapter 4. Europe Biodefense Market by Product
4.1 Europe Anthrax Market by Country
4.2 Europe Smallpox Market by Country
4.3 Europe Botulism Market by Country
4.4 Europe Radiation/nuclear Market by Country
4.5 Europe Other Product Market by Country

Chapter 5. Europe Biodefense Market by Country
5.1 Germany Biodefense Market
5.1.1 Germany Biodefense Market by Product
5.2 UK Biodefense Market
5.2.1 UK Biodefense Market by Product
5.3 France Biodefense Market
5.3.1 France Biodefense Market by Product
5.4 Russia Biodefense Market
5.4.1 Russia Biodefense Market by Product
5.5 Spain Biodefense Market
5.5.1 Spain Biodefense Market by Product
5.6 Italy Biodefense Market
5.6.1 Italy Biodefense Market by Product
5.7 Rest of Europe Biodefense Market
5.7.1 Rest of Europe Biodefense Market by Product

Chapter 6. Company Profiles
6.1 Xoma Corporation
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Altimmune, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Acquisition and Mergers:
6.2.4.2 Partnerships, Collaborations, and Agreements:
6.3 Emergent BioSolutions, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Research & Development Expense
6.3.4 Recent strategies and developments:
6.3.4.1 Acquisition and Mergers:
6.3.4.2 Partnerships, Collaborations, and Agreements:
6.4 Dynavax Technologies Corporation
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Research & Development Expense
6.5 SIGA Technologies, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.5.4.2 Approvals:
6.6 Elusys Therapeutics, Inc.
6.6.1 Company Overview
6.6.2 Recent strategies and developments:
6.6.2.1 Approvals:
6.7 Ichor Holdings, Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.8 Cleveland BioLabs, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.8.4 Recent strategies and developments:
6.8.4.1 Partnerships, Collaborations, and Agreements:
6.9 Bavarian Nordic A/S
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.9.5.2 Approvals:
6.10. Alnylam Pharmaceuticals, Inc.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Research & Development Expense
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo